TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06592326: A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 460 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06592326 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06592326 Rescue Dossier →